Verona Pharma PLC | Mutual Funds
Mutual Funds that own Verona Pharma PLC
Hargreave Hale AIM VCT 2 Plc
3,146,525
3.18%
3,084,024
7.43%
02/28/2017
Polar Capital Funds Plc - Biotechnology Fund
3,000,000
3.03%
0
0.96%
07/31/2018
Marlborough UK Micro Cap Growth Fund
2,853,747
2.88%
66,402
0.28%
03/29/2018
Fidelity Funds SICAV - European Smaller Companies Fund
1,626,720
1.64%
-4,018
0.2%
03/31/2018
1,442,478
1.46%
0
0.33%
03/31/2018
Aviva Investors Investment Funds ICVC - European Equity Fund
200,100
0.2%
-123,254
0.13%
10/15/2017
Aviva Investors - European Equity Fund
174,218
0.18%
-7,525
0.13%
06/30/2018
Hargreave Hale AIM VCT 1 Plc
111,429
0.11%
-791
0.18%
09/30/2017
Fidelity Funds SICAV - International Fund
82,503
0.08%
1,874
0.01%
03/31/2018
Fidelity Funds SICAV - Sélection Internationale
20,014
0.02%
352
0.02%
03/31/2018
| Address |
3 More London Riverside
London Greater London SE1 2RE
United Kingdom
|
|
Employees
|
- |
| Website |
http://veronapharma.com |
| Updated |
07/08/2019 |
| Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. Verona Pharma's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma. |
